Review
Biochemistry & Molecular Biology
Renlong Zhang, Junle Qu
Summary: This review comprehensively summarizes the mechanisms and effects of photobiomodulation (PBM) in arthritis treatment, as well as the development of animal models and evaluation methods used in clinical trials. It provides important references for future studies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Josko Mitrovic, Stela Hrkac, Josip Tecer, Majda Golob, Anja Ljilja Posavec, Helena Kolar Mitrovic, Lovorka Grgurevic
Summary: Rheumatoid arthritis (RA) is a prevalent autoimmune inflammatory chronic disease that primarily affects the joints but can also have extraarticular manifestations (EAMs) that impact various organs and increase the risk of cardiovascular disease (CVD), the leading cause of death in RA patients. Despite known risk factors, there is still limited understanding of the pathophysiology of EAMs. Better understanding the connections between joint and extra-joint manifestations could lead to improved treatments and patient care.
Review
Immunology
Sha Wu, Xiao-Feng Li, Yuan-Yuan Wu, Su-Qin Yin, Cheng Huang, Jun Li
Summary: Rheumatoid arthritis is characterized by immune cell infiltration and destruction of cartilage and bone. Studies have shown that m(6)A modification is related to the pathogenesis of RA, providing evidence for the development of new therapies. The relationship between m(6)A enzymes, immune cells, and RA is important for understanding and treating this autoimmune disease.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Menglin Zhu, Qian Ding, Zhongxiao Lin, Rong Fu, Fuyuan Zhang, Zhaoyi Li, Mei Zhang, Yizhun Zhu
Summary: Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes joint damage and disability, greatly impacting patients' quality of life. Although a complete cure is not currently possible, measures to relieve symptoms and reduce pain are used. RA can be induced by environmental factors, genes, and gender. Common treatments include non-steroidal anti-inflammatory drugs, disease-modifying anti-rheumatic drugs, and glucocorticoids. Some biological agents have been used but often have side effects. Therefore, the search for new mechanisms and targets for treating RA is crucial.
Review
Medicine, General & Internal
Raimon Sanmarti, Hector Corominas
Summary: Upadacitinib is a recently approved selective and reversible Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). This article provides an overview of the drug's chemical structure, mechanism of action, efficacy based on clinical trials, and safety profile. It also discusses the role of Upadacitinib in the management and therapeutic strategy of RA.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Multidisciplinary Sciences
Bin Zhao, Lingting Zeng, Danyang Chen, Songqing Xie, Zhaokui Jin, Guanglin Li, Wei Tang, Qianjun He
Summary: This study proposes a concept of photocatalytic regulation of the synovial microenvironment (SME) for arthritis treatment. Monodispersive hydrogen-doped titanium dioxide nanorods with a rutile single-crystal structure are developed to achieve near infrared-photocatalytic generation of hydrogen molecules and depletion of lactic acid (LA) in a collagen-induced mouse model of rheumatoid arthritis. The results show that locally produced hydrogen molecules scavenge reactive oxygen species and regulate the synovial microenvironment, thereby preventing synovial pannus formation and cartilage destruction.
Review
Pharmacology & Pharmacy
K. Logesh, Bhumika Raj, Mahendran Bhaskaran, Shailesh Thirumaleshwar, H. Gangadharappa, Riyaz Ali Osmani, K. M. Asha Spandana
Summary: Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects 1% of the world's population. Nanotechnology offers new possibilities for the treatment of RA by achieving specificity to joints and overcoming the limitations of conventional therapy. This review provides a comprehensive understanding of various nanoparticulate drug delivery systems and their application in the treatment of RA.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
(2023)
Review
Cell & Tissue Engineering
P. Luo, P. Wang, J. Xu, W. Hou, P. Xu, K. Xu, L. Liu
Summary: Rheumatoid arthritis is an autoimmune disease involving T and B cells and their interactions with proinflammatory cytokines. T cells, including Th1, Th2, Th17, and Tfh cells, play important roles in RA by secreting different cytokines and promoting joint destruction and disease progression.
BONE & JOINT RESEARCH
(2022)
Article
Rheumatology
Cynthia S. Crowson, Tina M. Gunderson, Hayley J. Dykhoff, Elena Myasoedova, Elizabeth J. Atkinson, Vanessa L. Kronzer, Caitrin M. Coffey, John M. Davis
Summary: This study comprehensively assessed the burden of multimorbidity in patients with rheumatoid arthritis (RA) and found that RA patients have a higher prevalence of multimorbidity compared to non-RA patients. Interstitial lung disease, fibromyalgia, osteoarthritis, and osteoporosis were common morbidities in RA patients.
Article
Medicine, General & Internal
Gabriele Di Sante, Elisa Gremese, Barbara Tolusso, Paola Cattani, Clara Di Mario, Simona Marchetti, Stefano Alivernini, Maria Tredicine, Luca Petricca, Ivana Palucci, Chiara Camponeschi, Virginia Aragon, Andrea Gambotto, Francesco Ria, Gianfranco Ferraccioli
Summary: The study revealed the presence of Haemophilus parasuis (Hps) DNA in the crevicular fluid of the majority of patients with rheumatoid arthritis (RA), and demonstrated the ability of Hps peptide to activate T cells specific to Coll(261-273), suggesting involvement in the pathogenesis of RA through molecular mimicry mechanism.
FRONTIERS IN MEDICINE
(2021)
Article
Rheumatology
Teresa A. Simon, Lixian Dong, Samy Suissa, Kaleb Michaud, Sofia Pedro, Marc Hochberg, Maarten Boers, Johan Askling, Thomas Frisell, Anja Strangfeld, Yvette Meissner, Vadim Khaychuk, Alyssa Dominique, Michael A. Maldonado
Summary: This study evaluated the risk of non-melanoma skin cancer associated with abatacept treatment for rheumatoid arthritis. The results suggest a potential increase in NMSC risk with abatacept use compared to conventional synthetic disease-modifying antirheumatic drugs.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Medicine, General & Internal
Lauren Covert, Heather Van Mater, Benjamin L. Hechler
Summary: The article emphasizes the impact of rheumatic conditions on the temporomandibular joint, outlining the importance of medical and surgical management in these patients, as well as highlighting the necessity for ongoing patient reassessment and monitoring.
Article
Pharmacology & Pharmacy
Merel A. A. Opdam, Sophie Benoy, Lise M. Verhoef, Sandra Van Bijnen, Femke Lamers-Karnebeek, Rene A. M. Traksel, Petra Vos, Alfons A. den Broeder, Jasper Broen
Summary: Patients with inflammatory rheumatic diseases do not have an increased risk for COVID-19 compared to the general population. Older age and obesity are major risk factors for hospitalization for COVID-19 in patients with IRD, while the use of methotrexate may have a protective effect in reducing the risk of hospitalization.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Biochemistry & Molecular Biology
Prachi Agnihotri, Hemchandra Deka, Debolina Chakraborty, Mohd Saquib, Uma Kumar, Sagarika Biswas
Summary: This study investigates the potential inhibitory effects of metabolites of rheumatoid arthritis (RA) on tumor necrosis factor alpha (TNF-a) and nuclear factor kappa B (NFkB). The results show that two metabolites (2-OHE2 and 16-Hydroxyestradiol) can attenuate the inflammation by inhibiting TNF-a and NF-kB, suggesting their potential for therapeutic targeting in RA.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
(2023)
Review
Immunology
Jie Huang, Xuekun Fu, Xinxin Chen, Zheng Li, Yuhong Huang, Chao Liang
Summary: Rheumatoid arthritis (RA) is a systemic poly-articular chronic autoimmune joint disease that affects a significant portion of the global population. While progress has been made with disease-modifying antirheumatic drugs, there is still a need for new therapeutic targets and approaches for some patients with limited response to existing treatments.
FRONTIERS IN IMMUNOLOGY
(2021)
